On the one hand, studies have shown that removing the pre-existing immunosuppressive environment of TME enhances the efficacy of anti-PD-1/PD-L1 and helps to overcome primary drug resistance in cancer patients [140, 141] (Fig. 3). The gene discussed is CD274; the disease is cancer.